

**VASCULITIS FOUNDATION**  
**FINANCIAL STATEMENTS**  
**June 30, 2017 and 2016**

VASCULITIS FOUNDATION

TABLE OF CONTENTS

	<u>Page</u>
Independent Auditors' Report .....	1-2
Financial Statements:	
Statements of Financial Position .....	3
Statements of Activities .....	4
Statements of Functional Expenses.....	5
Statements of Cash Flows.....	6
Notes to Financial Statements .....	7-11



4600 Madison, Suite 120  
Kansas City, MO 64112  
P 816.931.6111 F 816.931.8499

5831 Nieman Road, Suite 100  
Shawnee, KS 66203  
P 913.631.5626 F 913.631.5965

[www.novakbirkspc.com](http://www.novakbirkspc.com)

## INDEPENDENT AUDITORS' REPORT

To the Board of Directors  
Vasculitis Foundation  
Kansas City, Missouri

### **Report on the Financial Statements**

We have audited the accompanying financial statements of Vasculitis Foundation (a nonprofit Organization), which comprise the statements of financial position as of June 30, 2017 and 2016, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

### **Management's Responsibility for the Financial Statements**

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

### **Auditor's Responsibility**

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



## Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Vasculitis Foundation as of June 30, 2017 and 2016, and the changes in its net assets, functional expenses, and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

*Novak Birks PC*

Kansas City, Missouri  
Novak Birks, PC  
October 13, 2017

VASCULITIS FOUNDATION  
STATEMENTS OF FINANCIAL POSITION  
June 30, 2017 and 2016

	2017	2016
<u>ASSETS</u>		
Cash and cash equivalents	\$ 41,745	\$ 65,760
Funds held by Northland Community Foundation	1,278,446	984,873
Grants receivable	69,120	97,503
Prepaid expenses	2,435	2,609
Furniture and equipment, less accumulated depreciation	-	136
Total Assets	\$ 1,391,746	\$ 1,150,881
 <u>LIABILITIES AND NET ASSETS</u>		
Liabilities:		
Accounts payable	\$ 14,681	\$ 19,426
Accrued liabilities	46,147	37,713
Deferred revenue	0	8,325
Total Liabilities	60,828	65,464
Net Assets		
Unrestricted	201,282	81,351
Unrestricted - Board designated - endowment (Note E)	214,763	194,569
Total Unrestricted Net Assets	416,045	275,920
Temporarily restricted net assets	914,873	809,497
Total Net Assets	1,330,918	1,085,417
Total Liabilities and Net Assets	\$ 1,391,746	\$ 1,150,881

The accompanying notes are an integral part of  
this financial statement.

VASCULITIS FOUNDATION  
STATEMENTS OF ACTIVITIES  
For The Years Ended June 30, 2017 and 2016

	2017	2016
<b><u>UNRESTRICTED NET ASSETS</u></b>		
Revenues and Other Support:		
General donations	\$ 410,819	\$ 328,820
Dues	32,791	44,450
Memorials	81,781	35,150
In-kind contributions	1,023	3,857
Honors	19,318	17,681
Other	5,062	1,850
Symposium revenue	94,902	1,733
Interest and dividends	5,142	4,408
Unrealized gain (loss)	17,124	652
Realized gain (loss)	2,396	458
	670,358	439,059
Net Assets released from restrictions	700,477	548,581
	1,370,835	987,640
Expenses:		
Patient support, awareness, and research	1,070,852	847,205
Administrative	75,154	77,109
Fundraising	84,704	75,121
Total Expenses	1,230,710	999,435
Change in Unrestricted Net Assets	140,125	(11,795)
<b><u>TEMPORARILY RESTRICTED NET ASSETS</u></b>		
Revenues		
Restricted donations	781,489	475,714
Interest and dividends	12,181	11,415
Unrealized gain (loss)	8,881	2,868
Realized gain (loss)	3,302	1,360
Net asset released from restrictions	(700,477)	(548,581)
Change in Temporarily Restricted Net Assets	105,376	(57,224)
Change in Net Assets	245,501	(69,019)
Net Assets, beginning of year	1,085,417	1,154,436
Net Assets, end of year	\$ 1,330,918	\$ 1,085,417

The accompanying notes are an integral part of  
this financial statement.

VASCULITIS FOUNDATION  
STATEMENTS OF FUNCTIONAL EXPENSES  
For the Years Ended June 30, 2017 and 2016

	2017				2016			
	Patient Support, Awareness, and Research	Administrative	Fundraising	Total	Patient Support, Awareness, and Research	Administrative	Fundraising	Total
Supporting Services	\$ 209,576	\$ 24,749	\$ 10,735	\$ 245,060	\$ 228,476	\$ 24,462	\$ 10,535	\$ 263,473
Grants paid	331,884	-	-	331,884	331,447	-	-	331,447
Salaries and Wages	193,940	35,926	3,757	233,623	128,726	33,963	1,361	164,050
Newsletter	34,546	-	-	34,546	29,991	1,356	587	31,934
Symposium and conferences	201,686	-	-	201,686	14,646	-	-	14,646
Member information	50,041	-	-	50,041	71,369	-	-	71,369
Event costs	-	-	69,364	69,364	5,795	-	61,550	67,345
Payroll taxes and benefits	27,700	5,586	848	34,134	16,416	4,926	1,088	22,430
Board expenses	8,859	8,859	-	17,718	12,268	12,268	-	24,536
Medical Conferences	10,588	-	-	10,588	6,696	-	-	6,696
Depreciation	102	34	-	136	400	134	-	534
Memberships	1,930	-	-	1,930	975	-	-	975
<b>TOTAL EXPENSES</b>	<b>\$ 1,070,852</b>	<b>\$ 75,154</b>	<b>\$ 84,704</b>	<b>\$ 1,230,710</b>	<b>\$ 847,205</b>	<b>\$ 77,109</b>	<b>\$ 75,121</b>	<b>\$ 999,435</b>

The accompanying notes are an integral part of these financial statements.

VASCULITIS FOUNDATION  
 STATEMENTS OF CASH FLOWS  
 For The Years Ended June 30, 2017 and 2016

	2017	2016
Cash Flows From Operating Activities:		
Change in net assets	\$ 245,501	\$ (69,019)
Adjustments to reconcile increase in net assets to net cash flows from operating activities:		
Depreciation	136	534
Realized (gain) loss on investments	(26,005)	(3,520)
Unrealized (gain) loss on Investments	(5,698)	(1,818)
(Increase) decrease in:		
Grants receivable	28,383	(57,548)
Prepaid expenses	174	(2,609)
Increase (decrease) in:		
Accounts payable	(4,745)	13,606
Accrued liabilities	8,434	6,541
Deferred revenue	(8,325)	8,325
Net Cash Provided by Operating Activities	237,855	(105,508)
 Cash Flows From Investing Activities:		
Transfers from Northland Community Foundation	210,130	216,233
Transfers to Northland Community Foundation	(472,000)	(87,000)
Net Cash From (Used In) Investing Activities	(261,870)	129,233
 Net Change In Cash	(24,015)	23,725
 Cash, beginning of year	65,760	42,035
 Cash, end of year	\$ 41,745	\$ 65,760

The accompanying notes are an integral part of  
 this financial statement.



VASCULITIS FOUNDATION  
NOTES TO FINANCIAL STATEMENTS  
June 30, 2017 and 2016

NOTE A – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization – Vasculitis Foundation (The Foundation) is the largest patient support group and the only international organization for vasculitis patients and their loved ones. Vasculitis is a rare autoimmune disease that strikes people of all ages. There are at least fifteen known vasculitic diseases. There is no known cause or cure. Early diagnosis is critical to patients. Without effective treatment, the disease is fatal.

Through a newsletter, a website, information packets, medical consultants, symposiums, as well as area contacts and chapters, the Foundation works to raise awareness of vasculitis, educate patients about the disease, and support research into the cause, cure and treatment of the disease.

Donated Materials and Services – Donated materials are reflected as contributions in the accompanying financial statements at their fair values at the date of receipt. The Foundation records donated services to the extent that they create or enhance non-financial assets or that they require specialized skills, are provided by individuals possessing those skills, and would typically need to be purchased if not provided by donation. The Foundation had \$1,023 and \$3,856 of in-kind contributions for research and travel expenses for the years ended June 30, 2017 and 2016., respectively. Additionally, the Foundation had \$1,315 and \$5,055 in general in-kind contributions for the year ended June 30, 2017 and 2016., respectively.

Furniture and Equipment – The Foundation capitalizes all significant additions of property and equipment, which are recorded at acquisition cost if purchased, or fair value, if donated. Depreciation is provided on a straight line basis over three years.

Income Taxes – The Foundation qualifies as tax exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code.

The Foundation recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax position meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority.

The Foundation is subject to income tax regulations in the U.S. federal jurisdiction and certain state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. With few exceptions, the Foundation is no longer subject to income tax examinations by the applicable tax authorities for the years before 2014. If any were to be incurred, the Foundation's policy is to record penalties and interest assessed by income tax authorities as operating expenses.

Cash Equivalents – For purpose of the statement of cash flows, the Foundation considers highly liquid investments purchased with initial maturities of less than three months to be cash equivalents. Included in cash equivalents at June 30, 2017 and 2016 was \$19,098 and \$16,415, respectively, held in money market funds at an investment company that were not insured by the Federal Deposit Insurance Corporation.

VASCULITIS FOUNDATION  
NOTES TO FINANCIAL STATEMENTS  
June 30, 2017 and 2016

NOTE A – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Expense Allocation- The Foundation allocates its expenses on a functional basis among its program, administrative, and fundraising activities. Administrative expenses include those expenses that are not directly identifiable with any other specific function but provide for the overall support and direction of the Foundation.

Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

Research Funds – All donations that are designated for research are placed in the Foundation's Research Fund, which supports the Foundation's Research Program. The purpose of the Research Program is to provide one-year seed grants to support pilot studies in researching the etiology; epidemiology; diagnosis; treatment, including approaches that would prevent complications; and development of coping skills for living with the disease.

Awards are provided up to \$50,000 for a one-year study and up to \$100,000 for a two-year study. Smaller awards are also allowed. Suitable applicants are medical researchers in areas such as, but not limited to, rheumatology, immunology, nephrology, otolaryngology, pulmonary and respiratory diseases, and internal medicine.

Applications are reviewed by the Foundation's Research Committee and Scientific Advisory Board. Each investigator is required to submit a six-month progress report, including financial data. A final report is also required and is due within sixty days of the last day of the study and must also include a financial report. Donations designated for research may not be used to support any other program or activity of the Foundation, and are classified as temporarily restricted revenues and net assets.

Subsequent Events – Subsequent events have been evaluated through October 13, 2017, which is the date the financial statements were available to be issued.

NOTE B – FAIR VALUE MEASUREMENTS

FASB ASC 820, *Fair Value Measurements and Disclosures*, provides the framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements).

VASCULITIS FOUNDATION  
NOTES TO FINANCIAL STATEMENTS  
June 30, 2017 and 2016

NOTE B – FAIR VALUE MEASUREMENTS (Continued)

The three levels of the fair value hierarchy under FASB ASC 820 are described as follows:

- |         |  |
|---------|--|
| Level 1 | Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Plan has the ability access.   |
| Level 2 | Inputs to the valuation methodology include <ul style="list-style-type: none"><li>• quoted prices for similar assets or liabilities in active markets;</li><li>• quoted prices for identical or similar assets or liabilities in inactive markets;</li><li>• inputs other than quoted prices that are observable for the asset or liability;</li><li>• inputs that are derived principally from or corroborated by observable market data by correlation or other means.</li></ul> If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. |
| Level 3 | Inputs to the valuation methodology are unobservable and significant to the fair value measurement.  |

The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used at June 30, 2017 and 2016.

- Funds held by the Northland Community Foundation are valued based on quoted prices for the underlying securities assets or liabilities and are classified within Level 2 of the fair value hierarchy.

The following table sets forth by level, within the fair value hierarchy, the Plan's assets at fair value as of June 30, 2017 and 2016.

VASCULITIS FOUNDATION  
NOTES TO FINANCIAL STATEMENTS  
June 30, 2017 and 2016

NOTE B – FAIR VALUE MEASUREMENTS (Continued)

	<u>Assets at Fair Value as of June 30, 2017</u>			
	<u>Total</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Funds held by Northland Community Foundation:				
Money market pool	\$ 543,444	\$ -	\$ 543,444	\$ -
Fixed income pool	462,918	-	462,918	-
Equity pool	<u>272,084</u>	<u>-</u>	<u>272,084</u>	<u>-</u>
	<u>\$1,278,446</u>	<u>\$ -</u>	<u>\$ 1,278,446</u>	<u>\$ -</u>

	<u>Assets at Fair Value as of June 30, 2016</u>			
	<u>Total</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Funds held by Northland Community Foundation:				
Money market pool	\$ 365,007	\$ -	\$ 365,007	\$ -
Fixed income pool	388,796	-	388,796	-
Equity pool	<u>231,070</u>	<u>-</u>	<u>231,070</u>	<u>-</u>
	<u>\$ 984,873</u>	<u>\$ -</u>	<u>\$ 984,873</u>	<u>\$ -</u>

NOTE C – FURNITURE AND EQUIPMENT

Furniture and equipment consists of:

	<u>2017</u>	<u>2016</u>
Furniture and equipment	\$ 6,380	\$ 6,380
Website costs	<u>49,147</u>	<u>49,147</u>
	55,527	55,527
Accumulated depreciation	<u>(55,527)</u>	<u>(55,391)</u>
	<u>\$ -</u>	<u>\$ 136</u>

Depreciation expense was \$136 and \$533 for each of the years ended June 30, 2017 and 2016, respectively.

NOTE D – TEMPORARILY RESTRICTED NET ASSETS

Temporarily restricted net assets consisted of the following at June 30:

	<u>2017</u>	<u>2016</u>
Research	\$ 443,069	\$ 618,821
Patient education and support	<u>471,804</u>	<u>190,676</u>
	<u>\$ 914,873</u>	<u>\$ 809,497</u>

VASCULITIS FOUNDATION  
 NOTES TO FINANCIAL STATEMENTS  
 June 30, 2017 and 2016

**NOTE E – UNRESTRICTED BOARD DESIGNATED ENDOWMENT FUNDS**

The Foundation has set aside certain funds that it has board-designated to be treated similarly to an endowment. Such funds are to generate a long-term, total rate of return that will increase the value of the assets. The Foundation's endowment assets, which are held in various investment pools at the Northland Community Foundation, totaled \$214,763 and \$194,569 at June 30, 2017 and 2016, respectively.

The Foundation has established investment policies for its board-designated endowment fund. These policies provide for investing approximately 65% of the funds in the equity pool, approximately 35% in the fixed income pool, and less than 1% of the funds in the money market pool. All expenditures of these funds are approved by the Board of Directors. The following table presents a reconciliation of the beginning and ending balances of these endowment funds:

Balance at June 30, 2015	\$155,182
Expenditures and fees	(1,441)
Investment income	3,925
Gain on investments	<u>(1,512)</u>
Balance at June 30, 2016	<u>\$194,569</u>
Expenditures and fees	(1,422)
Investment income	4,376
Gain on investments	<u>17,240</u>
Balance at June 30, 2017	<u>\$214,763</u>

**NOTE F – CONCENTRATIONS**

The Foundation invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the value of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the accompanying statements of financial position.

A significant portion (38%) of the Foundation's fiscal 2017 revenues came from two donors.

**NOTE G – DEFERRED REVENUE**

The Foundation typically receives fees and registrations for Symposiums to be held at a future date. These funds are classified as deferred revenues until such time as the events occur. At that time, the fees are reclassified to current year revenues. Deferred revenues totaled \$8,325 at June 30, 2016. There were no deferred revenues at June 30, 2017.